BNP/CALL/ASTRAZENECA/12500/0.1/20.12.24 Stock

DE000PC3BUZ5

Market Closed - Boerse Frankfurt Warrants 11:20:52 2024-07-01 EDT
1.03 ^EUR	-3.74%

Current month	-3.74%
1 month	-0.96%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ASTRAZENECA PLC

Chart BNP/CALL/ASTRAZENECA/12500/0.1/20.12.24

Latest news about ASTRAZENECA PLC

European Equities Close Higher in Monday Trading; Eurozone Manufacturing Contraction Widens in June	12:12pm	MT
UK Stocks Flat; Manufacturing Sector Remains in Expansion Zone	12:12pm	MT
AstraZeneca : Transparency Directive Form 6 K	10:10am	PU
AstraZeneca's Potential Covid-19 Prevention Drug Gets EU Accelerated Assessment	08:35am	MT

More news

Quotes 5-day view

Date	Price	Change
24-07-01	1.03	-3.74%
24-06-28	1.07	+1.90%
24-06-27	1.05	-10.26%
24-06-26	1.17	-3.31%
24-06-25	1.21	+3.42%

Real-time Boerse Frankfurt Warrants

Last update July 01, 2024 at 11:20 am

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	ASTRAZENECA PLC
Issuer	BNP Paribas
WKN	PC3BUZ
ISIN	DE000PC3BUZ5
Date issued	2024-01-16
Strike	12,500 p
Maturity	2024-12-20 (172 Days)
Parity	10 : 1
Emission price	0.44 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	1.34 €
Lowest since issue	0.14 €
Spread	0.01 €
Spread %	0.96%

Company Profile

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

More about the company